Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Oncotelic Therapeutics, Inc. | d562604dex991.htm |
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 27, 2013
OXiGENE, INC.
(Exact name of registrant as specified in its charter)
Delaware | 0-21990 | 13-3679168 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
701 Gateway Boulevard, Suite 210, South San Francisco, CA 94080
(Address of principal executive offices)
Registrants telephone number, including area code: (650) 635-7000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
x | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On June 27, 2013, OXiGENE, Inc. filed a supplement (the Supplement) to its proxy statement for the annual meeting of stockholders to be held on July 16, 2013. The Supplement should be read together with the Proxy Statement dated as of June 13, 2013. In connection with the filing of the Supplement, OXiGENE has also posted the letter attached hereto as Exhibit 99.1 on its corporate website.
Item 9.01Financial Statements and Exhibits.
(d) | The following exhibit is filed with this report: |
Exhibit Number |
Description | |
99.1 | Letter to Stockholders. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OXiGENE, Inc. | ||||||
Date: July 1, 2013 | By: | /s/ Peter J. Langecker | ||||
Peter J. Langecker Chief Executive Officer |